Source: Menafn
Adaptin Bio Announces Opening Of Enrollment In A Phase 1 Clinical Trial Evaluating Treatment Of Malignant Brain Tumors With APTN-101
(MENAFN – GlobeNewsWire – Nasdaq) APTN-101's unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of
Key Points
- (MENAFN – GlobeNewsWire – Nasdaq) APTN-101's unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of
Published: August 20, 2026 4:16 pm
Source: Menafn